Stock IPA IMMUNOPRECISE ANTIBODIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News ImmunoPrecise Antibodies Ltd. Toronto S.E.

Equities

IPA

CA45257F2008

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
BU
ImmunoPrecise Antibodies Ltd. Appoints Kristin Taylor as Permanent Chief Financial Officer
CI
IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai
AQ
ImmunoPrecise Antibodies Unit, PGxAI to Develop AI Model to Predict Treatment Responses
MT
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
BU
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology
AQ
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
BU
Immunoprecise Antibodies Ltd. Announces the Commercial Release of Lens Ai API, Hereafter Referred to as the `Software', by Its Subsidiary, Biostrand
CI
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
BU
IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model for Electronic Health Records
AQ
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
BU
ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform
CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
CI
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
BU
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
BU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024
AQ
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation
PU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
BU
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPA Stock
  4. IPA Stock
  5. News ImmunoPrecise Antibodies Ltd.